Dianthus reports positive Phase 2 MaGic trial for claseprubart in gMG; both doses meet endpoints

Dianthus Therapeutics, Inc. /DE/

Claseprubart 300mg Q2W: MG-ADL mean change -4.6 (placebo-adjusted -1.8, p=0.0113); QMG -4.4 (adj. -2.4, p=0.0144) at Week 13.
Claseprubart 600mg Q2W: MG-ADL mean change -5.4 (adj. -2.6, p=0.0006); QMG -4.5 (adj. -2.5, p=0.0111).
Rapid onset: both doses showed stat. significant MG-ADL and QMG improvement as early as Week 1.
Favorable safety: no related serious infections, SAEs, or discontinuations; no Boxed Warning or REMS anticipated for planned autoinjector.
Phase 3 gMG trial evaluating 300mg Q2W and Q4W vs placebo planned to start in 2026; CIDP and MMN data expected 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.